[go: up one dir, main page]

EP0897389B1 - Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes - Google Patents

Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes Download PDF

Info

Publication number
EP0897389B1
EP0897389B1 EP97914363A EP97914363A EP0897389B1 EP 0897389 B1 EP0897389 B1 EP 0897389B1 EP 97914363 A EP97914363 A EP 97914363A EP 97914363 A EP97914363 A EP 97914363A EP 0897389 B1 EP0897389 B1 EP 0897389B1
Authority
EP
European Patent Office
Prior art keywords
diaminocyclohexane
dichloro
cis
oxalate
diammine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97914363A
Other languages
German (de)
French (fr)
Other versions
EP0897389A1 (en
Inventor
Yoshinori Kidani
Rolland-Yves Debiopharm S.A. MAUVERNAY
Teruko Irie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0897389A1 publication Critical patent/EP0897389A1/en
Application granted granted Critical
Publication of EP0897389B1 publication Critical patent/EP0897389B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a new class of complexes of dinuclear platinum. It also relates to a process for their preparation. The invention also relates to the pharmaceutical compositions containing them and their use for the therapeutic treatment of various cancers.
  • Cisplatin and oxaliplatin are cytostatic antineoplastic agents known, which are advantageously used in the therapeutic treatment of various cancers.
  • Cisplatin is especially prescribed for the treatment of cancers of the testes, ovaries, epidermoid cancers, for the treatment of tumors level of head, neck, etc.
  • Oxaliplatin is prescribed for the treatment of cancers of the same type, mainly ovarian cancer, as well as colon cancer, pathways upper respiratory tract and epidermoid cancers.
  • Each of these antineoplastic agents has its own specificity clean and, therefore, depending on the stage of the disease, the patient's condition or the type of cancer to be treated, the practitioner may have to prescribe one or the other of these agents. In some cases, however, the therapeutic effect sought is not reached or at least does not reach its maximum level.
  • cytostatic antineoplastic agents in particular other organometallic derivatives of platinum, cisplatin and oxaliplatin present an intrinsic toxicity which constitutes a serious limiting factor that the practitioner must take into account in the prescribed treatment.
  • Cisplatin presents in particular a significant renal and neuromotor toxicity, all the more that it turns out to be cumulative. It also causes strong vomiting and can cause bradycardia, as well as myelosuppression.
  • oxaliplatin causes reversible sensory dysesthesia which can easily be moderate the effects by appropriately modulating the dose administered to the patient. he However, it follows that the practitioner finds himself therapeutically limited in terms of healing in particular.
  • Oxaliplatin belongs to the class of platinum II complexes of trans-1,2-cyclohexanediamine which are currently in full development. said complex or "dach" complexes are the subject of clinical trials in Europe, especially in France, as well as in the United States and Japan and are particularly effective against melanomas and tumors of the ovaries, uterus, stomach and intestines, etc.
  • Patent EP-A-143,478 relates to a method of administration of cisplatin in the form of an acidic aqueous solution, more specifically acid hydrochloric acid having a pH preferably between 3.2 and 3.5 and containing chloride ions for example from sodium chloride to stabilize the solution and thus avoid hydrolysis.
  • US Patent 4,177,263 which also relates to cisplatin describes a method of treating cancerous tumors in animals by injecting parenterally a complex platinum agent in an amount effective for cause tumor regression.
  • the invention also relates to a process for the preparation of new dinuclear platinum complexes, characterized in that it consists in reacting in aqueous solution and in equimolar proportion two mononuclear platinum complexes, one of which is a di platinum complex halogenated C1 and the other a platinum complex C2 comprising either two monodentate ligands B or a bidentate ligand BB as defined above, so that a bridge is formed between the two complexes, in which X is as defined above.
  • step d) etbanol is advantageously used as alcohol.
  • C1 and C2 mononuclear complexes are the complexes of the following mononuclear platinum:
  • the mononuclear platinum complexes C1 and C2 are advantageously cisplatin and oxaliplatin.
  • the compounds of the present invention of formula (I) are principles active pharmaceutical compositions, the toxicity of which is compatible with their use as medicines.
  • the present invention relates to pharmaceutical compositions containing as active ingredient a complex of dinuclear platinum of formula (I) or (II).
  • Dosage units are formulated in pharmaceutical compositions in which the active ingredient is mixed with a pharmaceutical vehicle.
  • compositions containing the platinum complex of the invention, as an active ingredient can be administered by oral or parenteral (intramuscular or intravenous).
  • compositions may be in the form of tablets, capsules, powders, granules or any another form for oral administration.
  • Pharmaceutical compositions may also contain pharmaceutically acceptable vehicles compatible with the compounds of the invention.
  • the pharmaceutical compositions are preferably administered by parenteral (intramuscular - intravenous) route.
  • the injectable solutions are aqueous solutions containing at least one pharmaceutically acidic buffer acceptable free of chloride ions and a neutral substance serving as vehicle.
  • the pH of the solution for injection is adjusted to a value preferably between 6.8 and 7.
  • an acid or a mixture of acids is used organic and corresponding alkaline salts, pharmaceutically acceptable.
  • AT as organic acid preferably an amino acid dicarboxylic, such as aspartic or glutamic acid and, as alkaline salt, a lithium salt, corresponding sodium or potassium.
  • the mineral acid it can be used by example of acetic acid or phosphoric acid.
  • glutamic acid is used in presence or absence of sodium glutamate.
  • the composition also generally comprises a neutral substance acting as a vehicle, such as a carbohydrate such as lactose, glucose, mannitol or sorbitol or similar compounds.
  • a neutral substance acting as a vehicle such as a carbohydrate such as lactose, glucose, mannitol or sorbitol or similar compounds.
  • Such a solution can therefore be administered parenterally, if if necessary, together with other cytostatic agents, physico-chemically compatible with the dinuclear platinum complexes of the invention and in accordance with current practices in cancer therapy.
  • the compounds of the present invention exhibit anti-tumor activity against experimental tumors in mice, such as L 1210 and are therefore particularly useful in the chemotherapy of tumors.
  • the present invention relates to the use products of formula (I) for the preparation of medicaments intended to treat various cancers.
  • mice 10 5 mouse L 1210 leukemia cells in saline suspension were injected intraperitoneally into groups of 6 CDF1 mice on day 0.
  • the test compound was administered intraperitoneally 1, 3 and 5 days after the transplantation of the cells. cancerous.
  • the therapeutic efficacy of the compounds of the invention was measured by the T / C% ratio. This report represents 100 times the average survival time of the group having received the test compound divided by the mean survival time of the group of comparison which did not receive the test compound.
  • the numbers in parentheses represent the number of mice cured in a group of 6 mice.
  • the numbers in parentheses represent the number of cured mice in a group of 6 mice.
  • Tables 1 and 2 show the effectiveness of the dinuclear platinum complex of the invention as an anti-tumor agent.
  • the complex of the invention allowed the healing of 5 mice out of 6, against 2 out of 6 for the oxaliplatin / cisplatin combination and 1 in 6 for oxaliplatin (Table 1), knowing that a lower dose is not sufficient and a larger dose is toxic.
  • Rf distance traveled by the compound distance traveled by the mobile solvent
  • Rf is obtained by chromatography on paper (Toyo filter paper 2 x 20 cm) at room temperature using SnCl 2 as a detector.
  • EXAMPLE 1 Synthesis of a dinuclear platinum complex of 1-OHP and of cisplatin: [(cis-diammine) (1R, 2R-cyclohexanediamine) - ⁇ -dichloro-di-Pt (II)] oxalate or also [(NH 3 ) 2 Pt ( ⁇ -Cl) 2 Pt (trans-l-dach)] ox, hereinafter l-OHP.DDP: NCU 501 of chemical structure:
  • EXAMPLE 7 Synthesis of a dinuclear platinum complex of cisplatin and l-DN dach: [(cis-diammine) (1R, 2R-cyclohexanediamine) - ⁇ -dichloro-di-Pt (II)] Nitrate or also [(NH 3 ) 2 Pt ( ⁇ -Cl) 2 Pt (trans-l-dach)] (NO 3 ) 2 , hereinafter DDP.I-DN dach: NCU 507.
  • EXAMPLE 8 Synthesis of a dinuclear platinum complex of cisplatin and d-DN dach: [(cis-diammine) (1S, 2S-cyclohexanediamine) - ⁇ -dichloro-di-Pt (II)] Nitrate or also [(NH 3 ) 2 Pt ( ⁇ -Cl) 2 Pt (trans-d-dach)] (NO 3 ) 2 , hereinafter DDP.d-DN dach: NCU 508.
  • EXAMPLE 10 Synthesis of a dinuclear platinum complex of l-DC dach and l-DC dach: [bis (1R, 2R-cyclohexanediamine) - ⁇ -dichloro-di-Pt (II)] Nitrate or also [(trans- l-dach) Pt ( ⁇ -Cl) 2 Pt (trans-l-dach)] (NO 3 ) 2 , hereinafter l-DC dach.l-DN dach: NCU 510.
  • EXAMPLE 12 Synthesis of a dinuclear platinum complex of cis-DC dach and l-DN dach: [(1R, 2R-cyclohexanediamine) (R, S-cyclohexane diamine) - ⁇ -dichloro-di-Pt (II)] Nitrate or also [(trans-l-dach) Pt ( ⁇ -Cl) 2 Pt (cis-dach)] (NO 3 ) 2 , hereinafter cis-DC dach.l-DN dach: NCU 512.
  • EXAMPLE 13 Synthesis of a dinuclear platinum complex of DDP and CBDCA: [bis (cis-diammine) - ⁇ -dichloro-di-Pt (II)] 1,1-cyclobutanedicarboxylate, or also [(NH 3 ) 2 Pt ( ⁇ -Cl) 2 Pt (NH 3 ) 2 ] CBDCA, hereinafter DDP.CBDCA: NCU 513.
  • EXAMPLE 14 Synthesis of a dinuclear platinum complex of 1-OHP.Cl and of DDP: [(cis-diammine) (trans-dichloro) (1R, 2R-cyclohexanediamine) - ⁇ -dichloro-Pt (II) -Pt ( IV)] Oxalate or also [(NH 3 ) 2 Pt (II) ( ⁇ -Cl) 2 Pt (IV) (trans-Cl 2 -trans-l-dach)] Ox, hereinafter l-OHP.Cl- DDP: NCU 514.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

La présente invention a pour objet une nouvelle classe de complexes de platine dinucléaires. Elle a également pour objet un procédé pour leur préparation. L'invention concerne aussi les compositions pharmaceutiques les contenant et leur utilisation pour le traitement thérapeutique de divers cancers.The present invention relates to a new class of complexes of dinuclear platinum. It also relates to a process for their preparation. The invention also relates to the pharmaceutical compositions containing them and their use for the therapeutic treatment of various cancers.

Le cisplatine et l'oxaliplatine sont des agents antinéoplasiques cytostatiques connus, que l'on utilise avantageusement dans le traitement thérapeutique de divers cancers.Cisplatin and oxaliplatin are cytostatic antineoplastic agents known, which are advantageously used in the therapeutic treatment of various cancers.

Le cisplatine est notamment prescrit pour le traitement de cancers des testicules, des ovaires, de cancers épidermoïdes, pour le traitement des tumeurs au niveau de la tête, du cou, etc.Cisplatin is especially prescribed for the treatment of cancers of the testes, ovaries, epidermoid cancers, for the treatment of tumors level of head, neck, etc.

L'oxaliplatine est prescrit pour le traitement de cancers du même type, principalement le cancer des ovaires, ainsi que le cancer du colon, des voies respiratoires supéricures et les cancers épidermoïdes.Oxaliplatin is prescribed for the treatment of cancers of the same type, mainly ovarian cancer, as well as colon cancer, pathways upper respiratory tract and epidermoid cancers.

Chacun de ces agents antinéoplasiques possède une spécificité qui lui est propre et, de ce fait, en fonction du stade évolutif de la maladie, de l'état du patient ou du type de cancer à traiter, le praticien peut être amené à prescrire l'un ou l'autre de ces agents. Dans certains cas cependant, l'effet thérapeutique recherché n'est pas atteint ou pour le moins n'atteint pas son niveau maximum.Each of these antineoplastic agents has its own specificity clean and, therefore, depending on the stage of the disease, the patient's condition or the type of cancer to be treated, the practitioner may have to prescribe one or the other of these agents. In some cases, however, the therapeutic effect sought is not reached or at least does not reach its maximum level.

Tout comme d'autres agents antinéoplasiques cytostatiques, en particulier d'autres dérivés organométalliqucs du platine, le cisplatine et l'oxaliplatine présentent une toxicité intrinsèque qui constitue un facteur limitant sérieux que le praticien doit prendre en compte dans le traitement prescrit. Le cisplatine présente notamment une toxicité rénale ct neuromotrice non négligeable, d'autant plus qu'elle se révèle cumulative. Il provoque également de forts vomissements et peut entraíner une bradycardie, ainsi qu'une myélosuppression. A un degré moindre, l'oxaliplatine entraíne une dysesthésie sensorielle réversible dont on peut aisément modérer les effets en modulant convenablement la dose administrée au patient. Il s'en suit cependant que le praticien se trouve limité sur le plan thérapeutique en termes de moyens de guérison notamment.Just like other cytostatic antineoplastic agents, in particular other organometallic derivatives of platinum, cisplatin and oxaliplatin present an intrinsic toxicity which constitutes a serious limiting factor that the practitioner must take into account in the prescribed treatment. Cisplatin presents in particular a significant renal and neuromotor toxicity, all the more that it turns out to be cumulative. It also causes strong vomiting and can cause bradycardia, as well as myelosuppression. To a lesser degree, oxaliplatin causes reversible sensory dysesthesia which can easily be moderate the effects by appropriately modulating the dose administered to the patient. he However, it follows that the practitioner finds himself therapeutically limited in terms of healing in particular.

L'oxaliplatine appartient à la classe des complexes du platine II de trans-1,2-cyclohexanediamine qui sont actuellement en plein développement. Lesdits complexes ou complexes "dach" font l'objet d'essais cliniques en Europe, notamment en France, ainsi qu'aux Etats-Unis et au Japon et sont particulièrement efficaces contre les mélanomes et les tumeurs d'ovaires, d'utérus, de l'estomac et des intestins, etc.Oxaliplatin belongs to the class of platinum II complexes of trans-1,2-cyclohexanediamine which are currently in full development. said complex or "dach" complexes are the subject of clinical trials in Europe, especially in France, as well as in the United States and Japan and are particularly effective against melanomas and tumors of the ovaries, uterus, stomach and intestines, etc.

Le brevet US 4 169 846 décrit de tels complexes, à savoir des complexes de cis-platine (II) et de 1,2-cyclohexanediamine, en particulier le complexe [Pt(II) oxalato (1R, 2R-cyclohexanediamine)] qui est le composé connu sous la dénomination oxaliplatine.US Patent 4,169,846 describes such complexes, namely complexes of cis-platinum (II) and 1,2-cyclohexanediamine, in particular the complex [Pt (II) oxalato (1R, 2R-cyclohexanediamine)] which is the compound known as name oxaliplatin.

Lesdits complexes "dach", lorsqu'ils sont combinés avec le 5-fluorouracile (5FU), sont particulièrement efficaces contre le cancer de l'estomac.Said "dach" complexes, when combined with 5-fluorouracil (5FU), are particularly effective against stomach cancer.

De plus, lorsqu'ils sont combinés avec le 5-fluorouracile et l'acide folinique, les complexes "dach" sont particulièrement utiles pour le traitement du cancer du colon.In addition, when combined with 5-fluorouracil and acid folinic, "dach" complexes are particularly useful for the treatment of Colon Cancer.

Le brevet EP-A-143 478 concerne une méthode d'administration du cisplatine sous la forme d'une solution aqueuse acide, plus précisément d'acide chlorhydrique présentant un pH compris de préférence entre 3,2 et 3,5 et contenant des ions chlorure par exemple provenant de chlorure de sodium pour stabiliser la solution et éviter ainsi l'hydrolyse.Patent EP-A-143,478 relates to a method of administration of cisplatin in the form of an acidic aqueous solution, more specifically acid hydrochloric acid having a pH preferably between 3.2 and 3.5 and containing chloride ions for example from sodium chloride to stabilize the solution and thus avoid hydrolysis.

Le brevet US 4 177 263 qui concerne également le cisplatine décrit une méthode de traitement des tumeurs cancéreuses chez l'animal consistant à injecter par voie parentérale un agent complexe de platine en une quantité efficace pour causer la régression de la tumeur.US Patent 4,177,263 which also relates to cisplatin describes a method of treating cancerous tumors in animals by injecting parenterally a complex platinum agent in an amount effective for cause tumor regression.

Des essais cliniques menés en France sur l'utilisation de la combinaison de l'oxaliplatine et du cisplatine ont montré l'effet remarquable de ladite combinaison sur le cancer du foie. Cependant, on a pu constater l'existence de problèmes de stabilité des complexes associés.Clinical trials conducted in France on the use of the combination of oxaliplatin and cisplatin have shown the remarkable effect of said combination on liver cancer. However, we have seen the existence of stability of associated complexes.

La demande de brevet internationale WO94/12193 décrit notamment une composition destinée à l'administration conjointe de cisplatine et d'oxaliplatine sous la forme d'une combinaison après reconstitution extemporanée par addition de liquide aqueux se présentant sous forme d'un lyophilisat comprenant le cisplatine et l'oxaliplatine dans un rapport pondéral allant de 2:1 à 1:2.International patent application WO94 / 12193 describes in particular a composition for the combined administration of cisplatin and oxaliplatin in the form of a combination after extemporaneous reconstitution by addition of aqueous liquid in the form of a lyophilisate comprising cisplatin and oxaliplatin in a weight ratio ranging from 2: 1 to 1: 2.

On a maintenant trouvé une nouvelle famille de complexes de platine très stables ayant une activité anticancéreuse.We have now found a new family of very complex platinum stable with anticancer activity.

Les nouveaux complexes de l'invention répondent à l'une des formules générales (I) ou (II) :

Figure 00030001
Figure 00030002
dans lesquelles :

  • Y-Y représente un ligand bidentate amine de formule
    • NH2-R1-NH2 dans laquelle R1 représente un groupe alkylène linéaire ou ramifié en C2-C6 ou un groupe o-phénylène ;
    • ou un groupe de formule
      Figure 00030003
      dans laquelle
    • n = 2, 3, 4, 5
    • m = 0, 1,
    • et l = 0,1 ;
  • A1 et A2 représentent soit deux ligands monodentates identiques ammine, n-ou isopropylamine ou (C3-C7) cycloalkylamine, soit ils sont liés ensemble et forment un ligand bidentate amine de formule :
    • NH2-R1-NH2 dans laquelle R1 représente un groupe alkylène linéaire ou ramifié en C2-C6 ou un groupe o-phénylène ;
    • ou un groupe de formule
      Figure 00030004
      dans laquelle
    • n = 2, 3, 4, 5
    • m = 0, 1,
    • et l = 0, 1 ;
  • X représente un ligand de pontage entre les deux platines choisi parmi Cl, Br, F et I ;
  • le groupe dissociable Ld représente :
    • soit deux ligands B monodentates choisis parmi NO3 - ou R COO-, dans lequel R est un résidu d'acide gluconique ou glucuronique ;
    • soit le ligand B-B bidentate choisi parmi
      Figure 00040001
      dans lequel R représente l'hydrogène, le groupe méthyle, éthyle, phényle, benzyle ;
  • Hal est un atome d'halogène choisi parmi le Cl, Br, F et I.
The new complexes of the invention correspond to one of the general formulas (I) or (II):
Figure 00030001
Figure 00030002
in which :
  • YY represents a bidentate amine ligand of formula
    • NH 2 -R 1 -NH 2 in which R 1 represents a linear or branched C 2 -C 6 alkylene group or an o-phenylene group;
    • or a group of formula
      Figure 00030003
      in which
    • n = 2, 3, 4, 5
    • m = 0, 1,
    • and l = 0.1;
  • A 1 and A 2 represent either two identical monodentate ligands ammine, n- or isopropylamine or (C 3 -C 7 ) cycloalkylamine, or they are linked together and form a bidentate amine ligand of formula:
    • NH 2 -R 1 -NH 2 in which R 1 represents a linear or branched C 2 -C 6 alkylene group or an o-phenylene group;
    • or a group of formula
      Figure 00030004
      in which
    • n = 2, 3, 4, 5
    • m = 0, 1,
    • and l = 0.1;
  • X represents a bridging ligand between the two plates chosen from Cl, Br, F and I;
  • the dissociable group Ld represents:
    • either two ligands B monodentates chosen from NO 3 - or R COO - , in which R is a residue of gluconic or glucuronic acid;
    • either the BB bidentate ligand chosen from
      Figure 00040001
      wherein R represents hydrogen, methyl, ethyl, phenyl, benzyl;
  • Hal is a halogen atom chosen from Cl, Br, F and I.

Une famille de composés préférée de l'invention sont les composés de formule (I) ou (II) dans lesquelles :

  • Y-Y représente un ligand bidentate choisi parmi : éthylènediamine, o-phénylènediamine, triméthylènediamine, 1,2-cyclohexanediamine et 2-(aminométhyl) cyclohexylamine ;
  • X représente Cl ;
  • A1 et A2 représentent soit deux ligands monodentates ammine, soit ils sont liés ensemble et forment un ligand bidentate choisi parmi : éthylènediamine, o-phénylènediamine, triméthylènediamine, 1,2-cyclohexanediamine et 2-(aminométhyl) cyclohexylamine ;
  • Ld représente :
    • soit deux ligands B monodentates choisis parmi NO3 - ou RCOO-, dans lequel R est un résidu d'acide gluconique ou glucuronique ;
    • soit un ligand bidentate B-B choisi parmi SO4 2-, ou les dicarboxylates constitués par oxalate, malonate, 1,1-cyclobutanedicarboxylate;
  • Hal représente Cl.
A family of preferred compounds of the invention are the compounds of formula (I) or (II) in which:
  • YY represents a bidentate ligand chosen from: ethylenediamine, o-phenylenediamine, trimethylenediamine, 1,2-cyclohexanediamine and 2- (aminomethyl) cyclohexylamine;
  • X represents Cl;
  • A 1 and A 2 represent either two amine monodentate ligands, or they are linked together and form a bidentate ligand chosen from: ethylenediamine, o-phenylenediamine, trimethylenediamine, 1,2-cyclohexanediamine and 2- (aminomethyl) cyclohexylamine;
  • Ld represents:
    • either two ligands B monodentates chosen from NO 3 - or RCOO - , in which R is a residue of gluconic or glucuronic acid;
    • either a bidentate BB ligand chosen from SO 4 2- , or the dicarboxylates constituted by oxalate, malonate, 1,1-cyclobutanedicarboxylate;
  • Hal represents Cl.

L'invention concerne également un procédé pour la préparation des nouveaux complexes de platine dinucléaircs, caractérisé en ce qu'il consiste à faire réagir en solution aqueuse et en proportion équimolaire deux complexes de platine mononucléaires, dont l'un est un complexe de platine di-halogéné C1 et l'autre un complexe de platine C2 comportant soit deux ligands monodentates B soit un ligand bidentate B-B tels que définis ci-dessus, de telle sorte qu'il se forme un pont

Figure 00050001
entre les deux complexes, dans lequel X est tel que défini ci-dessus.The invention also relates to a process for the preparation of new dinuclear platinum complexes, characterized in that it consists in reacting in aqueous solution and in equimolar proportion two mononuclear platinum complexes, one of which is a di platinum complex halogenated C1 and the other a platinum complex C2 comprising either two monodentate ligands B or a bidentate ligand BB as defined above, so that a bridge is formed
Figure 00050001
between the two complexes, in which X is as defined above.

Selon un mode préféré de l'invention, le procédé consiste :

  • a) à dissoudre dans de l'eau distillée le complexe mononucléaire de platine C1 par chauffage au bain-made ;
  • b) à dissoudre de façon similaire à l'étape a) le complexe mononucléaire de platine C2 dans l'eau distillée ;
  • c) à mélanger les deux solutions et faire chauffer le mélange réactionnel à 80°C;
  • d) à abandonner le mélange réactionnel à la température ambiante ; et
  • e) à filtrer, laver à l'eau tiède, puis à l'alcool le précipité cristallin jaune pâle en forme d'aiguilles ou d'écailles résultant de l'étape d) ;
    • According to a preferred embodiment of the invention, the method consists:
  • a) dissolving the mononuclear complex of platinum C1 in distilled water by heating in a bain-made;
  • b) dissolving similarly in step a) the platinum mononuclear complex C2 in distilled water;
  • c) mixing the two solutions and heating the reaction mixture to 80 ° C;
  • d) leaving the reaction mixture at room temperature; and
  • e) to filter, wash with lukewarm water, then with alcohol the pale yellow crystalline precipitate in the form of needles or scales resulting from step d);

    • A l'étape d), on utilise avantageusement comme alcool de l'étbanol.In step d), etbanol is advantageously used as alcohol.

    Des exemples de complexes mononucléaires C1 et C2 sont les complexes de platine mononucléaires suivants :Examples of C1 and C2 mononuclear complexes are the complexes of the following mononuclear platinum:

    Complexes C1C1 complexes

    • le cisplatine [Pt(II) cis Cl2(NH3)2], ci-après "DDP",cisplatin [Pt (II) cis Cl 2 (NH 3 ) 2 ], hereinafter "DDP",
    • le complexe [Pt(II) Cl2 (1S, 2S-cyclohexanediamine)], ci-après "d-DC dach",the complex [Pt (II) Cl 2 (1S, 2S-cyclohexanediamine)], hereinafter "d-DC dach",
    • le complexe [Pt(II) Cl2 (1R, 2R-cyclohexanediamine)], ci-après "l-DC dach",the complex [Pt (II) Cl 2 (1R, 2R-cyclohexanediamine)], hereinafter "l-DC dach",
    • le complexe [Pt(II) Cl2 (1R, 2S-cyclohexanediamine)], ci-après "cis-DC dach",the complex [Pt (II) Cl 2 (1R, 2S-cyclohexanediamine)], hereinafter "cis-DC dach",
    • le complexe [Pt(IV) oxalato trans Cl2 (1R, 2R-cyclohexanediamine)], ci-après "l-OHP.Cl".the complex [Pt (IV) oxalato trans Cl 2 (1R, 2R-cyclohexanediamine)], hereinafter "l-OHP.Cl".
    Complexes C2C2 complexes

    • l'oxaliplatine : [Pt(II) oxalato (1R, 2R-cyclohexanediamine)], ci-après "l-OHP",oxaliplatin: [Pt (II) oxalato (1R, 2R-cyclohexanediamine)], hereinafter "l-OHP",
    • le complexe [Pt(II) oxalato (R, S-cyclohexanediamine)], ci-après "cis-OHP",the complex [Pt (II) oxalato (R, S-cyclohexanediamine)], below "Cis-OHP"
    • le complexe [Pt(II) (NO3)2 (1R, 2R-cyclohexanediamine)], ci-après "l-DN dach",the complex [Pt (II) (NO 3 ) 2 (1R, 2R-cyclohexanediamine)], hereinafter "l-DN dach",
    • le complexe [Pt(II) (NO3)2 (1S, 2S-cyclohexanediamine)], ci-après "d-DN dach", the complex [Pt (II) (NO 3 ) 2 (1S, 2S-cyclohexanediamine)], hereinafter "d-DN dach",
    • le complexe [Pt(II) (NO3)2 (1R, 2S-cyclohexanediamine)], ci-après "cis-DN dach",the complex [Pt (II) (NO 3 ) 2 (1R, 2S-cyclohexanediamine)], hereinafter "cis-DN dach",
    • le carboplatine [Pt(II) cisdiammine (1,1-cyclobutanedicarboxylate)], ci-après "CBDCA",carboplatin [Pt (II) cisdiammine (1,1-cyclobutanedicarboxylate)], below "CBDCA"
    • le complexe [Pt(IV) oxalato trans Cl2 (1R, 2R-cyclohexanediamine)], ci-après "l-OHP.Cl".the complex [Pt (IV) oxalato trans Cl 2 (1R, 2R-cyclohexanediamine)], hereinafter "l-OHP.Cl".

    Les complexes de platine mononucléaires C1 et C2 sont avantageusement le cisplatine et l'oxaliplatine.The mononuclear platinum complexes C1 and C2 are advantageously cisplatin and oxaliplatin.

    Les composés de la présente invention de formule (I) sont des principes actifs de compositions pharmaceutiques, dont la toxicité est compatible avec leur utilisation en tant que médicaments.The compounds of the present invention of formula (I) are principles active pharmaceutical compositions, the toxicity of which is compatible with their use as medicines.

    Ainsi, selon un autre de ses aspects, la présente invention concerne les compositions pharmaceutiques contenant en tant que principe actif un complexe de platine dinucléaire de formule (I) ou (II).Thus, according to another of its aspects, the present invention relates to pharmaceutical compositions containing as active ingredient a complex of dinuclear platinum of formula (I) or (II).

    Les composés de la présente invention sont administrés en unité de dosage. Les unités de dosage sont formulées dans des compositions pharmaceutiques dans lesquelles le principe actif est mélangé avec un véhicule pharmaceutique.The compounds of the present invention are administered in dosage units. Dosage units are formulated in pharmaceutical compositions in which the active ingredient is mixed with a pharmaceutical vehicle.

    Les compositions pharmaceutiques renfermant le complexe du platine dinucléaire de l'invention, en tant que principe actif, peuvent être administrées par voie orale ou parentérale (intramusculaire ou intraveineuse).Pharmaceutical compositions containing the platinum complex of the invention, as an active ingredient, can be administered by oral or parenteral (intramuscular or intravenous).

    Pour une administration par voie orale, les compositions pharmaceutiques peuvent se présenter sous forme de comprimés, gélules, poudres, granulés ou toute autre forme administrable par voie orale. Les compositions pharmaceutiques peuvent en outre contenir des véhicules pharmaceutiquement acceptables compatibles avec les composés de l'invention.For oral administration, the pharmaceutical compositions may be in the form of tablets, capsules, powders, granules or any another form for oral administration. Pharmaceutical compositions may also contain pharmaceutically acceptable vehicles compatible with the compounds of the invention.

    Les compositions pharmaceutiques sont de préférence administrées par voie parentérale (intramusculaire - intraveineuse). Les solutions injectables sont des solutions aqueuses contenant au moins un tampon acide pharmaceutiquement acceptable exempt d'ions chlorure et une substance neutre faisant office de véhicule.The pharmaceutical compositions are preferably administered by parenteral (intramuscular - intravenous) route. The injectable solutions are aqueous solutions containing at least one pharmaceutically acidic buffer acceptable free of chloride ions and a neutral substance serving as vehicle.

    De préférence, on ajuste le pH de la solution injectable à une valeur comprise de préférence entre 6,8 et 7.Preferably, the pH of the solution for injection is adjusted to a value preferably between 6.8 and 7.

    Selon l'invention, on utilise avantageusement à titre de tampon acide des acides minéraux ou organiques et leurs sels alcalins pharmaceutiquement acceptables, exempts d'ions chlorure. According to the invention, it is advantageous to use, as acid buffer, mineral or organic acids and their pharmaceutically alkaline salts acceptable, free of chloride ions.

    Plus particulièrement, on utilise un acide ou un mélange d'acides organiques et de sels alcalins correspondants, pharmaceutiquement acceptables. A titre d'acide organique, on utilise de préférence un acide aminé dicarboxylique, tel que l'acide aspartique ou glutamique et, à titre de sel alcalin, un sel de lithium, sodium ou potassium correspondant. Comme acide minéral, on peut utiliser par exemple de l'acide acétique ou de l'acide phosphorique.More particularly, an acid or a mixture of acids is used organic and corresponding alkaline salts, pharmaceutically acceptable. AT as organic acid, preferably an amino acid dicarboxylic, such as aspartic or glutamic acid and, as alkaline salt, a lithium salt, corresponding sodium or potassium. As the mineral acid, it can be used by example of acetic acid or phosphoric acid.

    A titre de tampon acide préférentiel, on utilise l'acide glutamique en présence ou non de glutamate de sodium.As preferential acid buffer, glutamic acid is used in presence or absence of sodium glutamate.

    Selon l'invention, la composition comprend également généralement une substance neutre faisant office de véhicule, tel qu'un carbohydrate comme le lactose, le glucose, le mannitol ou le sorbitol ou composés similaires.According to the invention, the composition also generally comprises a neutral substance acting as a vehicle, such as a carbohydrate such as lactose, glucose, mannitol or sorbitol or similar compounds.

    Une telle solution peut donc être administrée par voie parentérale, le cas échéant, conjointement à d'autres agents cytostatiques, physico-chimiquement compatibles avec les complexes de platine dinucléaires de l'invention et conformément aux pratiques ayant cours en thérapie anticancéreuse.Such a solution can therefore be administered parenterally, if if necessary, together with other cytostatic agents, physico-chemically compatible with the dinuclear platinum complexes of the invention and in accordance with current practices in cancer therapy.

    Les composés de la présente invention présentent une activité anti-tumorale contre les tumeurs expérimentales chez la souris, telles que L 1210 et sont donc particulièrement utiles dans la chimiothérapie des tumeurs.The compounds of the present invention exhibit anti-tumor activity against experimental tumors in mice, such as L 1210 and are therefore particularly useful in the chemotherapy of tumors.

    Selon un autre de ses aspects, la présente invention concerne l'utilisation des produits de formule (I) pour la préparation de médicaments destinés à traiter divers cancers.According to another of its aspects, the present invention relates to the use products of formula (I) for the preparation of medicaments intended to treat various cancers.

    ETUDE PHARMACOLOGIQUE : ACTIVITE ANTITUMORALEPHARMACOLOGICAL STUDY: ANTI-TUMOR ACTIVITY

    L'activité anti-tumorale des composés de l'invention a été mise en évidence par le test ci-après.The anti-tumor activity of the compounds of the invention has been demonstrated by the test below.

    EXPERIENCEEXPERIENCE

    105 cellules de leucémie L 1210 de souris en suspension saline ont été injectées par voie intrapéritonéale à des groupes de 6 souris CDF1 au jour 0. Le composé à tester a été administré par voie intrapéritonéale 1, 3 et 5 jours après la transplantation des cellules cancéreuses.10 5 mouse L 1210 leukemia cells in saline suspension were injected intraperitoneally into groups of 6 CDF1 mice on day 0. The test compound was administered intraperitoneally 1, 3 and 5 days after the transplantation of the cells. cancerous.

    On a constitué également des groupes de contrôle de 6 souris qui n'ont pas reçu les composés à tester.Control groups of 6 mice were also formed which did not received the test compounds.

    L'efficacité thérapeutique des composés de l'invention a été mesurée par le rapport T/C %. Ce rapport représente 100 fois le temps moyen de survie du groupe ayant reçu le composé à tester divisé par le temps moyen de survie du groupe de comparaison qui n'a pas reçu le composé à tester.The therapeutic efficacy of the compounds of the invention was measured by the T / C% ratio. This report represents 100 times the average survival time of the group having received the test compound divided by the mean survival time of the group of comparison which did not receive the test compound.

    Les résultats sont présentés dans les tableaux 1 et 2 ci-dessous :

    Figure 00080001
    The results are presented in Tables 1 and 2 below:
    Figure 00080001

    Les nombres entre parenthèses représentent le nombre de souris guéries dans un groupe de 6 souris.

    Figure 00080002
    The numbers in parentheses represent the number of mice cured in a group of 6 mice.
    Figure 00080002

    Les nombres entre parenthèses représentent le nombre de souris guéries dans un groupe de 6 souris. The numbers in parentheses represent the number of cured mice in a group of 6 mice.

    Les résultats présentés dans les tableaux 1 et 2 montrent l'efficacité du complexe de platine dinucléaire de l'invention en tant qu'agent antitumoral. En effet, à une dose efficace de 3,12 mg/kg, le complexe de l'invention a permis la guérison de 5 souris sur 6, contre 2 sur 6 pour la combinaison oxaliplatine /cisplatine et 1 sur 6 pour l'oxaliplatine (Tableau 1), sachant qu'une dose inférieure n'est pas suffisante et qu'une dose plus importante est toxique.The results presented in Tables 1 and 2 show the effectiveness of the dinuclear platinum complex of the invention as an anti-tumor agent. In Indeed, at an effective dose of 3.12 mg / kg, the complex of the invention allowed the healing of 5 mice out of 6, against 2 out of 6 for the oxaliplatin / cisplatin combination and 1 in 6 for oxaliplatin (Table 1), knowing that a lower dose is not sufficient and a larger dose is toxic.

    On constate, en outre, que lorsque les cellules de leucémie L 1210 sont préalablement traitées au cisplatine, le complexe de l'invention est très efficace à une dose de 1,56 mg/kg : 6 souris sur 6 sont guéries alors que la combinaison connue n'est pas du tout efficace (tableau 2).It is also found that when the L 1210 leukemia cells are previously treated with cisplatin, the complex of the invention is very effective in a dose of 1.56 mg / kg: 6 mice out of 6 are cured while the combination known is not at all effective (Table 2).

    STABILITESTABILITY

    On a vérifié d'autre part la stabilité des complexes de platine dinucléaires de l'invention par chromatographie sur papier.We also checked the stability of the dinuclear platinum complexes of the invention by chromatography on paper.

    La stabilité a été en effet évaluée par les valeurs de la caractéristique Rf : Rf = distance parcourue par le composédistance parcourue par le solvant mobile Rf est obtenu par chromatographie sur papier (papier filtre Toyo 2 x 20 cm) à la température ambiante en utilisant comme détecteur du SnCl2.The stability was indeed evaluated by the values of the characteristic Rf: Rf = distance traveled by the compound distance traveled by the mobile solvent Rf is obtained by chromatography on paper (Toyo filter paper 2 x 20 cm) at room temperature using SnCl 2 as a detector.

    Les résultats sont présentés dans le Tableau 3 ci-dessous.The results are presented in Table 3 below.

    Les produits de l'invention sont identifiés ci-après par un numéro de code NCU attribué par les inventeurs.

    Figure 00100001
    The products of the invention are identified below by an NCU code number assigned by the inventors.
    Figure 00100001

    L'invention va maintenant être illustrée de manière plus précise par les exemples illustratifs et non limitatifs ci-après :The invention will now be illustrated more precisely by the Illustrative and nonlimiting examples below:

    EXEMPLE 1 Synthèse d'un complexe de platine dinucléaire de l-OHP et de cisplatine : [(cis-diammine)(1R,2R-cyclohexanediamine)-µ-dichloro-di-Pt(II)] oxalate ou encore [(NH3)2Pt (µ-Cl)2 Pt (trans-l-dach)] ox, ci-après l-OHP.DDP : NCU 501 de structure chimique : EXAMPLE 1 Synthesis of a dinuclear platinum complex of 1-OHP and of cisplatin: [(cis-diammine) (1R, 2R-cyclohexanediamine) -µ-dichloro-di-Pt (II)] oxalate or also [(NH 3 ) 2 Pt (µ-Cl) 2 Pt (trans-l-dach)] ox, hereinafter l-OHP.DDP: NCU 501 of chemical structure:

    Figure 00100002
    Figure 00100002

    On dissout 0,60 g (2 mmole) de cisplatine (masse molaire = 299 g/mol) dans 90 ml d'eau distillée par chauffage au bain-marie (pH = 5,0). On dissout également 0,80 g (2 mmole) de l-OHP (masse molaire = 397 g/mol) dans 80 ml d'eau distillée en chauffant dans un bain-marie (pH = 5,0). Les deux solutions sont réunies puis on fait chauffer le mélange réactionnel à 80°C. Après 15-30 minutes, on obtient un précipité sous forme d'aiguilles de couleur jaune pâle. On filtre le précipité, lave à l'eau tiède puis à l'alcool. On obtient ainsi 0,61 g du complexe cristallin jaune pâle attendu avec un rendement de 87 %.0.60 g (2 mmol) of cisplatin is dissolved (molar mass = 299 g / mol) in 90 ml of distilled water by heating in a water bath (pH = 5.0). We dissolve also 0.80 g (2 mmol) of l-OHP (molar mass = 397 g / mol) in 80 ml distilled water by heating in a water bath (pH = 5.0). Both solutions are combined and then the reaction mixture is heated to 80 ° C. After 15-30 minutes, a precipitate is obtained in the form of pale yellow needles. We filter the precipitated, washed with lukewarm water and then with alcohol. 0.61 g of the complex is thus obtained pale yellow crystalline expected with a yield of 87%.

    Le spectre d'absorption aux infrarouges de ce complexe est représenté sur la figure 1. Analyse élémentaire : C8H20N4O4Pt2Cl2 (masse molaire = 697 g/mol). Calculé Trouvé C 13,77 % 13,98 % H 2,86 % 3,08 % N 8,03 % 8,06 % Pt 55,95 % 52,9 % The infrared absorption spectrum of this complex is shown in Figure 1. Elemental analysis: C 8 H 20 N 4 O 4 Pt 2 Cl 2 (molar mass = 697 g / mol). Calculated Find VS 13.77% 13.98% H 2.86% 3.08% NOT 8.03% 8.06% Pt 55.95% 52.9%

    EXEMPLE 2 Synthèse d'un complexe de platine dinucléaire de d-OHP et de cisplatine : [(cis-diammine) (1S, 2S-cyclohexanediamine)-µ-dichloro-di-Pt(II)]oxalate ou encore [(NH3)2Pt (µ-Cl)2 Pt(trans-d-dach)] Ox, ci-après d-OHP.DDP : NCU 502. EXAMPLE 2 Synthesis of a dinuclear platinum complex of d-OHP and cisplatin: [(cis-diammine) (1S, 2S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] oxalate or also [(NH 3 ) 2 Pt (µ-Cl) 2 Pt (trans-d-dach)] Ox, hereinafter d-OHP.DDP: NCU 502.

    On dissout 0,60 g (2 mmole) de cisplatine dans 90 ml d'eau distillée par chauffage au bain-marie (pH = 5,0). On dissout également 0,80 g (2 mmole) de d-OHP dans 80 ml d'eau distillée en chauffant dans un bain-marie (pH = 5,0). Les deux solutions sont réunies puis on fait chauffer le mélange réactionnel à 80°C. Après 15-30 minutes, on obtient un précipité sous forme d'aiguilles de couleur jaune pâle. On filtre le précipité, lave à l'eau tiède puis à l'alcool. On obtient ainsi 0,60 g du complexe cristallin jaune pâle attendu avec un rendement de 86 %.0.60 g (2 mmol) of cisplatin is dissolved in 90 ml of distilled water heating in a water bath (pH = 5.0). Also dissolved 0.80 g (2 mmol) of d-OHP in 80 ml of distilled water by heating in a water bath (pH = 5.0). The two solutions are combined and then the reaction mixture is heated to 80 ° C. After 15-30 minutes, a precipitate is obtained in the form of colored needles pale yellow. The precipitate is filtered, washed with lukewarm water and then with alcohol. We thus obtain 0.60 g of the pale yellow crystalline complex expected with a yield of 86%.

    Le spectre d'absorption aux infrarouges est représenté sur la figure 2. Analyse élémentaire : C8H20N4O4Pt2Cl2 (masse molaire = 697 g/mol). Calculé Trouvé C 13,77 % 13,60 % H 2,86 % 2,96 % N 8,03 % 8,09 % Pt 55,95 % --- The infrared absorption spectrum is shown in Figure 2. Elemental analysis: C 8 H 20 N 4 O 4 Pt 2 Cl 2 (molar mass = 697 g / mol). Calculated Find VS 13.77% 13.60% H 2.86% 2.96% NOT 8.03% 8.09% Pt 55.95% ---

    EXEMPLE 3 Synthèse d'un complexe de platine dinucléaire de cis-OHP et de cisplatine : [(cis-diammine) (R, S-cyclohexanediamine)-µ-dichloro-di-Pt(II)]oxalate ou encore [(NH3)2Pt (µ-Cl)2 Pt(cis-dach)] Ox, ci-après cis-OHP.DDP : NCU 503. EXAMPLE 3 Synthesis of a dinuclear platinum complex of cis-OHP and of cisplatin: [(cis-diammine) (R, S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] oxalate or also [(NH 3 ) 2 Pt (µ-Cl) 2 Pt (cis-dach)] Ox, hereinafter cis-OHP.DDP: NCU 503.

    On dissout 0,60 g (2 mmole) de cisplatine dans 90 ml d'eau distillée par chauffage au bain-marie (pH = 5,0). On dissout également 0,80 g (2 mmole) de cis-OHP dans 80 ml d'eau distillée par chauffage au bain-marie (pH = 5,0). Les deux solutions sont réunies et à nouveau chauffées pendant une heure. Après concentration de la solution au 1/3 - 1/2 du volume initial et repos du mélange, on obtient des cristaux en forme d'aiguilles de couleur jaune pâle. On filtre les cristaux, les lave à l'eau tiède puis à l'alcool. On obtient ainsi 0,61 g du complexe cristallin attendu sous la forme d'aiguilles de couleur jaune pâle avec un rendement de 87 %.0.60 g (2 mmol) of cisplatin is dissolved in 90 ml of distilled water heating in a water bath (pH = 5.0). Also dissolved 0.80 g (2 mmol) of cis-OHP in 80 ml of distilled water by heating in a water bath (pH = 5.0). The two solutions are combined and heated again for one hour. After concentration of the solution to 1/3 - 1/2 of the initial volume and rest of the mixture, we obtains pale yellow needle-shaped crystals. We filter the crystals, wash them with lukewarm water and then with alcohol. 0.61 g of the complex is thus obtained expected lens in the form of pale yellow needles with a yield 87%.

    Le spectre d'absorption aux infrarouges est représenté sur la figure 3. Analyse élémentaire : C8H20N4O4Pt2Cl2 (masse molaire = 696 g/mol). Calculé Trouvé C 13,77 % 13,78 % H 2,86 % 2,90 % N 8,03 % 8,03 % Pt 55,95 % --- The infrared absorption spectrum is shown in Figure 3. Elemental analysis: C 8 H 20 N 4 O 4 Pt 2 Cl 2 (molar mass = 696 g / mol). Calculated Find VS 13.77% 13.78% H 2.86% 2.90% NOT 8.03% 8.03% Pt 55.95% ---

    EXEMPLE 4 Synthèse d'un complexe de platine dinucléaire de l-OHP et de l-DC dach : [bis(1R, 2R-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Oxalate ou encore [(trans-l-dach) Pt (µ-Cl)2Pt(trans-l-dach)] Ox, ci-après l-OHP.l-DC dach : NCU 504. EXAMPLE 4 Synthesis of a dinuclear platinum complex of 1-OHP and 1-DC dach: [bis (1R, 2R-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Oxalate or also [(trans-1 -dach) Pt (µ-Cl) 2 Pt (trans-l-dach)] Ox, hereinafter l-OHP.l-DC dach: NCU 504.

    On dissout 0,40 g (1 mmole) de l-OHP dans 40 ml d'eau distillée par chauffage au bain-marie. On dissout également 0,38 g (1 mmole) de l-DC dach (masse molaire = 379 g/mol) dans 300 ml d'eau distillée par chauffage au bain-marie. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel pendant environ 1 heure. Après avoir laissé reposer le mélange réactionnel à température ambiante, on obtient des cristaux en forme d'aiguilles de couleur jaune pâle. Après filtration, les cristaux sont lavés à l'eau tiède, puis à l'alcool donnant 0,30 g du complexe cristallin attendu sous la forme d'aiguilles de couleur jaune pâle avec un rendement de 39 %. Analyse élémentaire : C14H28N4O4Pt2Cl2 (masse molaire = 777 g/mol). Calculé Trouvé C 21,62 % 20,82 % H 3,60 % 3,84 % N 7,20 % 7,38 % Pt 50,19 % --- 0.40 g (1 mmol) of 1-OHP is dissolved in 40 ml of distilled water by heating in a water bath. 0.38 g (1 mmol) of l-DC dach (molar mass = 379 g / mol) is also dissolved in 300 ml of distilled water by heating in a water bath. The two solutions are combined and then the reaction mixture is boiled for about 1 hour. After allowing the reaction mixture to stand at room temperature, pale yellow needle-shaped crystals are obtained. After filtration, the crystals are washed with lukewarm water, then with alcohol, giving 0.30 g of the expected crystalline complex in the form of pale yellow needles with a yield of 39%. Elemental analysis: C 14 H 28 N 4 O 4 Pt 2 Cl 2 (molar mass = 777 g / mol). Calculated Find VS 21.62% 20.82% H 3.60% 3.84% NOT 7.20% 7.38% Pt 50.19% ---

    EXEMPLE 5 Synthèse d'un complexe de platine dinucléaire de l-OHP et de d-DC dach : [(1R, 2R-cyclohexanediamine) (1S, 2S-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Oxalate ou encore [(trans-l-dach) Pt (µ-Cl)2Pt(trans-d-dach)] Ox, ci-après l-OHP.d-DC dach : NCU 505. EXAMPLE 5 Synthesis of a dinuclear platinum complex of 1-OHP and d-DC dach: [(1R, 2R-cyclohexanediamine) (1S, 2S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Oxalate or again [(trans-l-dach) Pt (µ-Cl) 2 Pt (trans-d-dach)] Ox, hereinafter l-OHP.d-DC dach: NCU 505.

    On dissout 0,40 g (1 mmole) de l-OHP dans 40 ml d'eau distillée par chauffage au bain-marie et 0,38 g (1 mmole) de d-DC dach (masse molaire = 379 g/mol) dans 300 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel pendant environ 1 heure. Après avoir laissé reposer le mélange réactionnel à température ambiante, on obtient des cristaux en forme d'aiguilles de couleur jaune pâle. Après filtration, les cristaux sont lavés à l'eau tiède puis à l'alcool donnant 0,30 g du complexe cristallin avec un rendement de 39 %. Analyse élémentaire : C14H28N4O4Pt2Cl2 (masse molaire = 777 g/mol). Calculé Trouvé C 21,62 % 21,52 % H 3,60 % 3,99 % N 7,20 % 7,05 % Pt 50,19 % --- 0.40 g (1 mmol) of l-OHP is dissolved in 40 ml of distilled water by heating in a water bath and 0.38 g (1 mmol) of d-DC dach (molar mass = 379 g / mol) in 300 ml similarly distilled water. The two solutions are combined and then the reaction mixture is boiled for about 1 hour. After allowing the reaction mixture to stand at room temperature, pale yellow needle-shaped crystals are obtained. After filtration, the crystals are washed with lukewarm water and then with alcohol, giving 0.30 g of the crystalline complex with a yield of 39%. Elemental analysis: C 14 H 28 N 4 O 4 Pt 2 Cl 2 (molar mass = 777 g / mol). Calculated Find VS 21.62% 21.52% H 3.60% 3.99% NOT 7.20% 7.05% Pt 50.19% ---

    EXEMPLE 6 Synthèse d'un complexe de platine dinucléaire de l-OHP et de cis-DC dach : [(1R, 2R-cyclohexanediamine) (R, S-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Oxalate ou encore [(trans-l-dach) Pt (µ-Cl)2Pt(cis-dach)] Ox , ci-après l-OHP.cis DC dach NCU 506. EXAMPLE 6 Synthesis of a dinuclear platinum complex of 1-OHP and cis-DC dach: [(1R, 2R-cyclohexanediamine) (R, S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Oxalate or again [(trans-l-dach) Pt (µ-Cl) 2 Pt (cis-dach)] Ox, hereinafter l-OHP.cis DC dach NCU 506.

    On dissout 0,40 g (1 mmole) de l-OHP dans 40 ml d'eau distillée par chauffage au bain-marie. On dissout également 0,38 g (1 mmole) de cis-DC dach (masse molaire = 379 g/mol) dans 30 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel pendant environ 1 heure. Après avoir laissé reposer le mélange réactionnel à température ambiante, on obtient des cristaux en forme d'aiguilles de couleur jaune. On filtre le précipité, lave à l'eau tiède, puis à l'alcool. On obtient ainsi 0,28 g du complexe cristallin attendu sous la forme d'aiguilles de couleur jaune avec un rendement de 36%. Analyse élémentaire : C14H28N4O4Pt2Cl2 (masse molaire = 777 g/mol) Calculé Trouvé C 21,62 % 20,91 % H 3,60 % 3,55 % N 7,20 % 7,05 % Pt 50,19 % --- 0.40 g (1 mmol) of 1-OHP is dissolved in 40 ml of distilled water by heating in a water bath. 0.38 g (1 mmol) of cis-DC dach (molar mass = 379 g / mol) is also dissolved in 30 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled for about 1 hour. After allowing the reaction mixture to stand at room temperature, yellow needle-shaped crystals are obtained. The precipitate is filtered, washed with lukewarm water, then with alcohol. 0.28 g of the expected crystalline complex is thus obtained in the form of yellow needles with a yield of 36%. Elemental analysis: C 14 H 28 N 4 O 4 Pt 2 Cl 2 (molar mass = 777 g / mol) Calculated Find VS 21.62% 20.91% H 3.60% 3.55% NOT 7.20% 7.05% Pt 50.19% ---

    EXEMPLE 7 Synthèse d'un complexe de platine dinucléaire de cisplatine et de l-DN dach : [(cis-diammine) (1R, 2R-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Nitrate ou encore [(NH3)2 Pt (µ-Cl)2Pt(trans-l-dach)] (NO3)2, ci-après DDP.I-DN dach : NCU 507. EXAMPLE 7 Synthesis of a dinuclear platinum complex of cisplatin and l-DN dach: [(cis-diammine) (1R, 2R-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Nitrate or also [(NH 3 ) 2 Pt (µ-Cl) 2 Pt (trans-l-dach)] (NO 3 ) 2 , hereinafter DDP.I-DN dach: NCU 507.

    On dissout 0,299 g (1 mmole) de cisplatine dans 50 ml d'eau distillée par chauffage au bain-marie (pH environ 5,0). On dissout également 0,433 g (1 mmole) de l-DN dach (masse molaire = 433 g/mol) dans 20 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel. Après environ 30 minutes, on obtient un précipité cristallin en forme d'écailles de couleur jaune très pâle. On filtre le précipité, lave à l'eau tiède, puis à l'alcool. On obtient ainsi 0,30 g du complexe cristallin attendu avec un rendement de 36 %. Analyse élémentaire : C6H20N6O6Pt2Cl2 (masse molaire = 829 g/mol). Calculé Trouvé C 20,26 % 19,75 % H 2,41 % 2,78 % N 10,13 % 10,29 % Pt 47,04 % --- 0.299 g (1 mmol) of cisplatin is dissolved in 50 ml of distilled water by heating in a water bath (pH approximately 5.0). 0.433 g (1 mmol) of l-DN dach (molar mass = 433 g / mol) is also dissolved in 20 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled. After about 30 minutes, a crystalline precipitate in the form of very pale yellow scales is obtained. The precipitate is filtered, washed with lukewarm water, then with alcohol. 0.30 g of the expected crystalline complex is thus obtained with a yield of 36%. Elemental analysis: C 6 H 20 N 6 O 6 Pt 2 Cl 2 (molar mass = 829 g / mol). Calculated Find VS 20.26% 19.75% H 2.41% 2.78% NOT 10.13% 10.29% Pt 47.04% ---

    EXEMPLE 8 Synthèse d'un complexe de platine dinucléaire de cisplatine et de d-DN dach : [(cis-diammine) (1S, 2S-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Nitrate ou encore [(NH3)2 Pt (µ-Cl)2Pt(trans-d-dach)] (NO3)2, ci-après DDP.d-DN dach : NCU 508. EXAMPLE 8 Synthesis of a dinuclear platinum complex of cisplatin and d-DN dach: [(cis-diammine) (1S, 2S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Nitrate or also [(NH 3 ) 2 Pt (µ-Cl) 2 Pt (trans-d-dach)] (NO 3 ) 2 , hereinafter DDP.d-DN dach: NCU 508.

    On dissout 0,299 g (1 mmole) de cisplatine dans 50 ml d'eau distillée par chauffage au bain-marie (pH environ 5,0). On dissout également 0,433 g (1 mmole) de d-DN dach (masse molaire = 433 g/mol) dans 20 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel. Après environ 30 minutes, on obtient un précipité cristallin en forme d'écailles, de couleur jaune très pâle. On filtre le précipité, lave à l'eau tiède, puis à l'alcool. On obtient ainsi 0,28 g du complexe cristallin attendu avec un rendement de 34 %. Analyse élémentaire : C6H20N6O6Pt2Cl2 (masse molaire = 829 g/mol). Calculé Trouvé C 20,26 % 20,16 % H 2,41 % 2,31 % N 10,13 % 10,03 % Pt 47,04 % --- 0.299 g (1 mmol) of cisplatin is dissolved in 50 ml of distilled water by heating in a water bath (pH approximately 5.0). 0.433 g (1 mmol) of d-DN dach (molar mass = 433 g / mol) is also dissolved in 20 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled. After about 30 minutes, a very pale yellow, crystalline precipitate is obtained in the form of scales. The precipitate is filtered, washed with lukewarm water, then with alcohol. 0.28 g of the expected crystalline complex is thus obtained with a yield of 34%. Elemental analysis: C 6 H 20 N 6 O 6 Pt 2 Cl 2 (molar mass = 829 g / mol). Calculated Find VS 20.26% 20.16% H 2.41% 2.31% NOT 10.13% 10.03% Pt 47.04% ---

    EXEMPLE 9 Synthèse d'un complexe de platine dinucléaire de cisplatine et de cis-DN dach : [(cis-diammine) (R, S-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Nitrate ou encore [(NH3)2 Pt (µ-Cl)2Pt(cis-dach)] (NO3)2, ci-après DDP.cis-DN dach : NCU 509. EXAMPLE 9 Synthesis of a dinuclear platinum complex of cisplatin and cis-DN dach: [(cis-diammine) (R, S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Nitrate or also [(NH 3 ) 2 Pt (µ-Cl) 2 Pt (cis-dach)] (NO 3 ) 2 , hereinafter DDP.cis-DN dach: NCU 509.

    On dissout 0,299 g (1 mmole) de cisplatine dans 50 ml d'eau distillée par chauffage au bain-marie (pH environ 5,0). On dissout également 0,433 g (1 mmole) de cis-DN dach (masse molaire = 433 g/mol) dans 20 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel. Après environ 30 minutes, on obtient un précipité cristallin en forme d'écailles de couleur jaune très pâle. On filtre le précipité, lave à l'eau tiède, puis à l'alcool. On obtient ainsi 0,28 g du complexe cristallin attendu avec un rendement de 34 %. Analyse élémentaire : C6H20N6O6Pt2Cl2 (masse molaire = 829 g/mol). Calculé Trouvé C 20,26 % 20,05 % H 2,41 % 2,25 % N 10,13 % 10,01 % Pt 47,04 % --- 0.299 g (1 mmol) of cisplatin is dissolved in 50 ml of distilled water by heating in a water bath (pH approximately 5.0). 0.433 g (1 mmol) of cis-DN dach (molar mass = 433 g / mol) is also dissolved in 20 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled. After about 30 minutes, a crystalline precipitate in the form of very pale yellow scales is obtained. The precipitate is filtered, washed with lukewarm water, then with alcohol. 0.28 g of the expected crystalline complex is thus obtained with a yield of 34%. Elemental analysis: C 6 H 20 N 6 O 6 Pt 2 Cl 2 (molar mass = 829 g / mol). Calculated Find VS 20.26% 20.05% H 2.41% 2.25% NOT 10.13% 10.01% Pt 47.04% ---

    EXEMPLE 10 Synthèse d'un complexe de platine dinucléaire de l-DC dach et de l-DC dach : [bis (1R, 2R-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Nitrate ou encore [(trans-l-dach) Pt (µ-Cl)2Pt(trans-l-dach)] (NO3)2, ci-après l-DC dach.l-DN dach : NCU 510. EXAMPLE 10 Synthesis of a dinuclear platinum complex of l-DC dach and l-DC dach: [bis (1R, 2R-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Nitrate or also [(trans- l-dach) Pt (µ-Cl) 2 Pt (trans-l-dach)] (NO 3 ) 2 , hereinafter l-DC dach.l-DN dach: NCU 510.

    On dissout 0,38 g (1 mmole) de l-DC dach dans 300 ml d'eau distillée par chauffage au bain-marie (pH environ 5,0). On dissout également 0,433 g (1 mmole) de l-DN dach (masse molaire = 433 g/mol) dans 20 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionncl. Après environ 30 minutes, on obtient un precipité cristallin en forme d'écailles de couleur jaune très pâle. Ces cristaux sont filtrés, lavés à l'eau tiède, puis à l'alcool. On obtient ainsi 0,20 g du complexe cristallin attendu avec un rendement de 25 %. Analyse élémentaire : C12H28N6O6Pt2Cl2 (masse molaire = 813 g/mol). Calculé Trouvé C 17,71 % 18,05 % H 3,44 % 3,40 % N 10,33 % 9,79% Pt 47,37 % --- 0.38 g (1 mmol) of 1-DC dach is dissolved in 300 ml of distilled water by heating in a water bath (pH approximately 5.0). 0.433 g (1 mmol) of l-DN dach (molar mass = 433 g / mol) is also dissolved in 20 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled. After about 30 minutes, a crystalline precipitate in the form of very pale yellow scales is obtained. These crystals are filtered, washed with lukewarm water, then with alcohol. 0.20 g of the expected crystalline complex are thus obtained with a yield of 25%. Elemental analysis: C 12 H 28 N 6 O 6 Pt 2 Cl 2 (molar mass = 813 g / mol). Calculated Find VS 17.71% 18.05% H 3.44% 3.40% NOT 10.33% 9.79% Pt 47.37% ---

    EXEMPLE 11 Synthèse d'un complexe de platine dinucléaire de d-DC dach et de l-DN dach : [(1R,2R-cyclohexanediamine) (1S,2S-cyclohexanediamine)-µ-dichloro-di-Pt(II)] Nitrate ou encore [(trans-l-dach) Pt (µ-Cl)2Pt(trans-d-dach)] (NO3)2, ci-après d-DC dach.l-DN dach : NCU 511. EXAMPLE 11 Synthesis of a dinuclear platinum complex of d-DC dach and l-DN dach: [(1R, 2R-cyclohexanediamine) (1S, 2S-cyclohexanediamine) -µ-dichloro-di-Pt (II)] Nitrate or also [(trans-l-dach) Pt (µ-Cl) 2 Pt (trans-d-dach)] (NO 3 ) 2 , hereinafter d-DC dach.l-DN dach: NCU 511.

    On dissout 0,38 g (1 mmole) de d-DC dach dans 300 ml d'eau distillée par chauffage au bain-marie (pH environ 5,0). On dissout également 0,433 g (1 mmole) de 1-DN dach (masse molaire = 433 g/mol) dans 20 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel. Après environ 30 minutes, on obtient un précipité cristallin en forme d'écailles de couleur jaune très pâle. Ces cristaux sont filtrés, lavés à l'eau tiède, puis à l'alcool. On obtient ainsi 0,20 g du complexe cristallin attendu avec un rendement de 25 %. Analyse élémentaire : C12H28N6O6Pt2Cl2 (masse molaire = 813 g/mol). Calculé Trouvé C 17,71 % 17,65 % H 3,44 % 3,34 % N 10,33 % 10,30 % Pt 47,97 % --- 0.38 g (1 mmol) of d-DC dach is dissolved in 300 ml of distilled water by heating in a water bath (pH approximately 5.0). 0.433 g (1 mmol) of 1-DN dach (molar mass = 433 g / mol) is also dissolved in 20 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled. After about 30 minutes, a crystalline precipitate in the form of very pale yellow scales is obtained. These crystals are filtered, washed with lukewarm water, then with alcohol. 0.20 g of the expected crystalline complex are thus obtained with a yield of 25%. Elemental analysis: C 12 H 28 N 6 O 6 Pt 2 Cl 2 (molar mass = 813 g / mol). Calculated Find VS 17.71% 17.65% H 3.44% 3.34% NOT 10.33% 10.30% Pt 47.97% ---

    EXEMPLE 12 Synthèse d'un complexe de platine dinucléaire de cis-DC dach et de l-DN dach : [(1R,2R-cyclohexanediamine) (R,S-cyclohexane diamine)-µ-dichloro-di-Pt(II)] Nitrate ou encore [(trans-l-dach) Pt (µ-Cl)2Pt(cis-dach)] (NO3)2, ci-après cis-DC dach.l-DN dach : NCU 512. EXAMPLE 12 Synthesis of a dinuclear platinum complex of cis-DC dach and l-DN dach: [(1R, 2R-cyclohexanediamine) (R, S-cyclohexane diamine) -µ-dichloro-di-Pt (II)] Nitrate or also [(trans-l-dach) Pt (µ-Cl) 2 Pt (cis-dach)] (NO 3 ) 2 , hereinafter cis-DC dach.l-DN dach: NCU 512.

    On dissout 0,38 g (1 mmole) de cis-DC dach dans 300 ml d'eau distillée par chauffage au bain-marie (pH environ 5,0). On dissout également 0,433 g (1 mmole) de l-DN dach (masse molaire = 433 g/mol) dans 20 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel pendant 30 minutes. Après concentration de la solution à 50 % du volume initial, on abandonne le mélange à la température ambiante. On obtient un précipité cristallin en forme d'aiguilles de couleur jaune très pâle. Ces cristaux sont filtrés, lavés à l'eau tiède, puis à l'alcool. On obtient ainsi 0,15 g du complexe cristallin attendu avec un rendement de 18 %. Analyse élémentaire : C12H28N6O6Pt2Cl2 (masse molaire = 813 g/mol). Calculé Trouvé C 17,71 % 18,01 % H 3,44 % 3,45 % N 10,33 % 10,23 % Pt 47,97 % --- 0.38 g (1 mmol) of cis-DC dach is dissolved in 300 ml of distilled water by heating in a water bath (pH approximately 5.0). 0.433 g (1 mmol) of l-DN dach (molar mass = 433 g / mol) is also dissolved in 20 ml of distilled water in a similar manner. The two solutions are combined and then the reaction mixture is boiled for 30 minutes. After concentration of the solution to 50% of the initial volume, the mixture is left at room temperature. A crystalline precipitate in the form of very pale yellow needles is obtained. These crystals are filtered, washed with lukewarm water, then with alcohol. 0.15 g of the expected crystalline complex is thus obtained with a yield of 18%. Elemental analysis: C 12 H 28 N 6 O 6 Pt 2 Cl 2 (molar mass = 813 g / mol). Calculated Find VS 17.71% 18.01% H 3.44% 3.45% NOT 10.33% 10.23% Pt 47.97% ---

    EXEMPLE 13 Synthèse d'un complexe de platine dinucléaire de DDP et CBDCA : [bis (cis-diammine)-µ-dichloro-di-Pt(II)] 1,1-cyclobutanedicarboxylate, ou encore [(NH3)2Pt (µ-Cl)2 Pt (NH3)2] CBDCA, ci-après DDP.CBDCA : NCU 513. EXAMPLE 13 Synthesis of a dinuclear platinum complex of DDP and CBDCA: [bis (cis-diammine) -µ-dichloro-di-Pt (II)] 1,1-cyclobutanedicarboxylate, or also [(NH 3 ) 2 Pt ( µ-Cl) 2 Pt (NH 3 ) 2 ] CBDCA, hereinafter DDP.CBDCA: NCU 513.

    On dissout 0,30 g (1 mmole) de DDP dans 50 ml d'eau distillée en portant à ébullition. On ajoute ensuite 0,37 g (1 mmole) de CBDCA au milieu réactionnel et une goutte de HCl 1N, et on fait bouillir à nouveau le mélange pendant 30 minutes. Après 30 minutes environ, on obtient des cristaux de couleur marron jaunâtre en forme d'aiguilles. On filtre, lave à l'eau chaude, puis à l'alcool. On obtient ainsi 0,50 g du complexe cristallin attendu avec un rendement de 75 %.0.30 g (1 mmol) of DDP is dissolved in 50 ml of distilled water, bringing to boiling. 0.37 g (1 mmol) of CBDCA is then added to the reaction medium and a drop of 1N HCl, and the mixture is boiled again for 30 minutes. After about 30 minutes, yellowish brown crystals are obtained in shape of needles. It is filtered, washed with hot water, then with alcohol. We thus obtain 0.50 g of the expected crystalline complex with a yield of 75%.

    Le spectre d'absorption aux infrarouges se trouve à la figure 4. Analyse élémentaire C6H12N4O4Pt2Cl2 (masse molaire = 671 g/mol). Calculé Trouvé C 10,73 % 10,18 % H 2,68 % 2,14 % N 8,34 % 8,33 % Pt 58,12 % --- The infrared absorption spectrum is shown in Figure 4. Elementary analysis C 6 H 12 N 4 O 4 Pt 2 Cl 2 (molar mass = 671 g / mol). Calculated Find VS 10.73% 10.18% H 2.68% 2.14% NOT 8.34% 8.33% Pt 58.12% ---

    EXEMPLE 14 Synthèse d'un complexe de platine dinucléaire de l-OHP.Cl et de DDP : [(cis-diammine) (trans-dichloro) (1R, 2R-cyclohexanediamine)-µ-dichloro-Pt(II)-Pt(IV)] Oxalate ou encore [(NH3)2Pt(II) (µ-Cl)2 Pt(IV) (trans-Cl2-trans-l-dach)] Ox, ci-après l-OHP.Cl-DDP : NCU 514. EXAMPLE 14 Synthesis of a dinuclear platinum complex of 1-OHP.Cl and of DDP: [(cis-diammine) (trans-dichloro) (1R, 2R-cyclohexanediamine) -µ-dichloro-Pt (II) -Pt ( IV)] Oxalate or also [(NH 3 ) 2 Pt (II) (µ-Cl) 2 Pt (IV) (trans-Cl 2 -trans-l-dach)] Ox, hereinafter l-OHP.Cl- DDP: NCU 514.

    On dissout 0,47 g (1 mmole) de l-OHP.Cl (masse molaire = 469 g/mol) dans 50 ml d'eau distillée en chauffant dans un bain-marie et 0,3 g (1 mmole) de DDP (masse molaire = 299 g/mol) dans 30 ml d'eau distillée de façon similaire. Les deux solutions sont réunies puis on fait bouillir le mélange réactionnel pendant 30 minutes. On obtient des précipités cristallins de couleur jaune très pâle lorsque la réaction est terminée. Les précipités sont filtrés, lavés à l'eau tiède, puis à l'alcool donnant 0,33 g du complexe cristallin attendu avec un rendement de 50 %.0.47 g (1 mmol) of l-OHP.Cl is dissolved (molar mass = 469 g / mol) in 50 ml of distilled water by heating in a water bath and 0.3 g (1 mmol) of DDP (molar mass = 299 g / mol) in 30 ml of similarly distilled water. The two solutions are combined and then the reaction mixture is boiled for 30 minutes. Very pale yellow crystalline precipitates are obtained when the reaction is over. The precipitates are filtered, washed with lukewarm water, then with alcohol giving 0.33 g of the expected crystalline complex with a yield of 50%.

    Le spectre d'absorption aux infrarouges se trouve à la figure 5. Analysc élémentaire : C8H20N4O4Cl4Pt2 (masse molaire = 768 g/mol). Calculé Trouvé C 12,53 % 12,50 % H 2,61 % 2,75 % N 7,29 % 7,40 % Pt 50,78 % --- The infrared absorption spectrum is shown in Figure 5. Elementary analysis: C 8 H 20 N 4 O 4 Cl 4 Pt 2 (molar mass = 768 g / mol). Calculated Find VS 12.53% 12.50% H 2.61% 2.75% NOT 7.29% 7.40% Pt 50.78% ---

    Claims (7)

    1. A compound of formula (I) or (II):
      Figure 00290001
      Figure 00290002
      wherein:
      Y-Y is an amine bidentate ligand of the formula:
      NH2-R1-NH2 in which R1 is a C2-C6 linear or branched alkylene group or an o-phenylene group;
      or a group of the formula:
      Figure 00290003
      wherein
      n = 2, 3, 4, 5;
      m = 0 or 1 and
      1 = 0 or 1;
      A1 and A2 represent either two identical ammine monodentate ligands, n-isopropylamine or (C3-C7) cycloalkylamine or they are bonded together thereby forming an amine bidentate ligand of the formula:
      NH2-R1-NH2 in which R1 is a C2-C6 linear or branched alkylene group or an o-phenylene group;
      or a group of the formula:
      Figure 00300001
      wherein
      n = 2, 3, 4, 5;
      m = 0 or 1 and
      1 = 0 or 1;
      X represents a bridging ligand linking the two platinum atoms selected from Cl, Br, F and I;
      the dissociable Ld group represents:
      either two monodentate B-B ligands selected from NO3 - or RCOO-, in which R is a residue of gluconic or glucuronic acid;
      or the bidentate B-B ligand selected from: SO4 2-, -OOC-COO-,
      Figure 00300002
      wherein R is hydrogen, methyl, ethyl, phenyl or benzyl; and
      Hal is a halogen atom selected from the group consisting of Cl, Br, F and I.
    2. The compound of formula (I) or (II) according to claim 1, characterized by the fact that :
      Y-Y represents a bidentate ligand selected from ethylenediamine, o-phenylenediamine, trimethylenediamine, 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine;
      X is Cl;
      A1 and A2 represent either two ammine monodentate ligands or they are bonded together thereby forming a bidentate ligand selected from: ethylenediamine, o-phenylenediamine, trimethylenediamine, 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine;
      Ld is:
      either two monodentate B ligands selected from NO3 -, or RCOO- in which R is a residue of gluconic and glucuronic acid;
      or the bidentate ligand B-B selected from, SO4 2- or dicarboxylates consiting of oxolate, malonate 1,1-cyclobutanedicarboxylate; and
      Hal is Cl.
    3. The compound of formula (I) or (II) according to claim 1, wherein said compound is selected from:
      [(cis-diammine)(1R, 2R-diaminocyclohexane)-µ-dichloro-di-Pt(II)] oxalate;
      [(cis-diammine)(1S,2S-diaminocyclohexane)-µ-dichloro-di-Pt(II)] oxalate,
      [(cis-diammine)(R, S-diaminocyclohexane)-µ-dichloro-di-Pt(II)] oxalate,
      [bis(1R, 2R-diaminocyclohexane)-µ-dichloro-di-Pt(II)] oxalate;
      [(1R,2R-diaminocyclohexane) (1S, 2S-diaminocyclohexane)-µ-dichloro-di-Pt(II)] oxalate;
      [(1R, 2R-diaminocyclohexane) (R,S-diaminocyclohexane-µ-dichloro-di-Pt(II)] oxalate;
      [(cis-diammine)(1R, 2R-diaminocyclohexane)-µ-dichloro-di-Pt(II)] nitrate;
      [(cis-diammine)(1S, 2S-diaminocyclohexane)-µ-dichloro-di-Pt(II)] nitrate;
      [(cis-diammine) (R, S-diaminocyclohexane)-µ-dichloro-di-Pt(II) ] nitrate;
      [bis (1R, 2R-diaminocyclohexane)-µ-dichloro-di-Pt(II)] nitrate;
      [(1R, 2R-diaminocyclohexane)(1S, 2S-diaminocyclohexane)-µ-dichloro-di-Pt(II)] nitrate;
      [(1R, 2R-diaminocyclohexane)(R, S-diaminocyclohexane)-µ -dichloro-di-Pt(II)] nitrate;
      [bis (cis-diammine)-µ-dichloro-di-Pt(II)]1,1-cyclobutanedicarboxylate;
      [(cis-diammine)(transdichloro-(1R, 2R-diaminocyclohexane)-µ-dichloro-Pt(II)-Pt(IV)] oxalate.
    4. A process for the preparation of a compound of formula (I) or (II), characterized in that it consists of reacting, in an aqueous solution and in equimolar proportion, two mononuclear platinum complexes, one of which is a di-halogenated platinum complex C1 and the other a platinum complex C2 comprising either two monodentate B ligands or one bidentate B-B ligand as defined in claim 1 such that a bridge:
      Figure 00330001
      is formed between the two complexes, in which X is as defined in claim 1.
    5. The process according to claim 4, which further consists of:
      a) dissolving the mononuclear platinum complex C1 in distilled water by the application of heat in a water-bath;
      b) dissolving, as in step a), the mononuclear platinum complex C2 in distilled water;
      c) mixing the two solutions and heating the reaction mixture at 80°C;
      d) allowing the reaction mixture to stand at room temperature; and
      e) filtering and washing the needle- or scale-shaped pale yellow crystalline precipitate which forms in step
      d) with warm water and then with alcohol.
    6. The process according to claim 5 complex C1 is selected from:
      cisplatin: [Pt(II)cis Cl2 (NH3)2];
      [Pt(II)Cl2 (1S, 2S-diaminocyclohexane)];
      [Pt(II)-Cl2 (1R,2R-diaminocyclohexane)];
      [Pt(II)-Cl2 (1R,2S-diaminocyclohexane));
      [Pt(IV)-oxalate trans Cl2 (1R, 2R-diaminocyclohexane)],
      and the complex C2 is selected from :
      oxaliplatin: [Pt(II)oxalate (1R, 2R-diaminocyclohexane)];
      [Pt(II)oxalate(R, S-diaminocyclohexane)];
      [Pt(II)(NO3)2(1R, 2R-diaminocyclohexane)];
      [Pt(II)(NO3)2 (1S, 2S-diaminocyclohexane)];
      [Pt(II)(NO3)2 (1R, 2S-diaminocyclohexane)] ;
      carboplatin: [Pt(II)cis-diammine (1,1-cyclobutanedicarboxylate)];
      [Pt(IV)-oxalate trans Cl2 (1R, 2R-diaminocyclohexane)].
    7. A pharmaceutical composition containing a compound according to any one of claims 1 to 3 as the active principle.
    EP97914363A 1996-03-11 1997-03-10 Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes Expired - Lifetime EP0897389B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    FR9603017 1996-03-11
    FR9603017 1996-03-11
    PCT/FR1997/000419 WO1997033894A1 (en) 1996-03-11 1997-03-10 Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes

    Publications (2)

    Publication Number Publication Date
    EP0897389A1 EP0897389A1 (en) 1999-02-24
    EP0897389B1 true EP0897389B1 (en) 2002-07-03

    Family

    ID=9490047

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP97914363A Expired - Lifetime EP0897389B1 (en) 1996-03-11 1997-03-10 Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes

    Country Status (6)

    Country Link
    US (1) US6153646A (en)
    EP (1) EP0897389B1 (en)
    JP (1) JP3862758B2 (en)
    AU (1) AU2163797A (en)
    DE (1) DE69713763T2 (en)
    WO (1) WO1997033894A1 (en)

    Cited By (1)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions

    Families Citing this family (7)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
    DE10314377A1 (en) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid
    US20050090544A1 (en) * 2003-08-28 2005-04-28 Whittaker Darryl V. Oxaliplatin formulations
    PL1695991T3 (en) 2003-12-10 2010-05-31 Toudai Tlo Ltd Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same
    JP5201572B2 (en) 2005-06-09 2013-06-05 ナノキャリア株式会社 Method for producing polymerized coordination compound of platinum complex
    CZ300664B6 (en) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterile liquid pharmaceutical composition and process for preparing thereof
    CZ300665B6 (en) * 2007-01-22 2009-07-15 Pliva-Lachema A. S. Sterile liquid pharmaceutical composition and process for preparing thereof

    Family Cites Families (7)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US4101565A (en) * 1977-05-09 1978-07-18 Celanese Corporation Hydroformylation catalyst
    US4283342A (en) * 1980-01-31 1981-08-11 University Of Delaware Anticancer agents and methods of manufacture
    US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
    ATE52517T1 (en) * 1983-05-10 1990-05-15 Andrulis Res Corp BIS PLATINUM COMPLEXES AS AN ANTI-TUMORROW AGENT.
    AU581101B2 (en) * 1985-09-06 1989-02-09 Sankyo Company Limited Anti-tumour platinum complexes, their preparation and their use
    US5107007A (en) * 1989-09-01 1992-04-21 The University Of Vermont And State Agricultural College Bis-platinum complexes as chemotherapeutic agents
    JPH02275891A (en) * 1988-12-29 1990-11-09 Tsumura & Co Novel binuclear platinum complex and antitumor agent containing the same complex as active ingredient

    Cited By (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US7829113B2 (en) 2005-03-10 2010-11-09 Mebiopharm Co., Ltd. Liposome compositions
    US8758810B2 (en) 2005-03-10 2014-06-24 Mebiopharm Co., Ltd. Liposome compositions

    Also Published As

    Publication number Publication date
    EP0897389A1 (en) 1999-02-24
    AU2163797A (en) 1997-10-01
    JP2000506855A (en) 2000-06-06
    DE69713763T2 (en) 2003-03-13
    WO1997033894A1 (en) 1997-09-18
    DE69713763D1 (en) 2002-08-08
    JP3862758B2 (en) 2006-12-27
    US6153646A (en) 2000-11-28

    Similar Documents

    Publication Publication Date Title
    EP0193936B1 (en) Liposoluble platinum (ii) complex and preparation thereof
    CN102741262B (en) Pharmaceutical compositions containing cyclometalated N-heterocyclic carbene complexes for the treatment of cancer
    US9688709B2 (en) Phosphaplatins and their use for treatment of cancers
    US5624919A (en) Trans platinum (IV) complexes
    NL8004752A (en) MEDICINE AGAINST CANCER ON THE BASIS OF A PLATINUM COMPOUND, METHOD FOR THE PREPARATION THEREOF AND THE PLATINUM COMPOUND USED THEREOF.
    JPH08259581A (en) Platinum complex
    EP0897389B1 (en) Binuclear platinum complexes, method for preparing same and pharmaceutical compositions containing said complexes
    FR2459246A1 (en) CIS-LACTATE COMPLEXES OF PLATINUM (II) AMINE, MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    US7087214B2 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
    US4687780A (en) Anti-tumor compounds of platinum
    US6130245A (en) Dinuclear platinum complexes as cisplatin analogs for cancer treatment
    US6313333B1 (en) Multinuclear cationic platinum complexes with antitumor activity
    US6011166A (en) Trinuclear cationic platinum complexes having antitumor activity and pharmaceutial compositions containing them
    JP2009143913A (en) Tumor-inhibiting platinum (ii) oxalate complex
    CN112266396B (en) An integrated prodrug based on bioorthogonal chemistry, preparation method and medical use thereof
    JPH0248590A (en) Water-soluble platinum complex of novel malonate derivative
    US6458983B1 (en) Method for synthesizing complexes of platinum with iminoethers and their use as antitumoral drugs and nucleotide-base modifiers
    JPS63264594A (en) Antitumor agent
    NZ199887A (en) Phenanthroline derivatives and pharmaceutical compositions
    JPH01272592A (en) Novel platinum-containing compound and remedy for malignant tumor
    LU84365A1 (en) PLATINUM-DIAMINE COMPLEXES, PROCESS FOR OBTAINING SAME, APPLICATION OF SUCH A COMPLEX FOR OBTAINING A MEDICAMENT FOR THE TREATMENT OF CANCER AND THE MEDICINAL PRODUCT THUS OBTAINED
    JPS6245593A (en) Platinum complex of antitumor agent
    AU2003210192A1 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
    JPS5910596A (en) Bis(thiocyanate)palladium complex and drug composition
    CN1048321A (en) The preparation of drug combination method that contains heterocyclic carbamate derivatives

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19980910

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): DE FR GB

    17Q First examination report despatched

    Effective date: 20010418

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): DE FR GB

    REF Corresponds to:

    Ref document number: 69713763

    Country of ref document: DE

    Date of ref document: 20020808

    GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

    Effective date: 20021002

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed

    Effective date: 20030404

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 69713763

    Country of ref document: DE

    Representative=s name: WABLAT LANGE KARTHAUS ANWALTSSOZIETAET, DE

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 69713763

    Country of ref document: DE

    Representative=s name: WABLAT LANGE KARTHAUS ANWALTSSOZIETAET, DE

    Effective date: 20120911

    Ref country code: DE

    Ref legal event code: R081

    Ref document number: 69713763

    Country of ref document: DE

    Owner name: KIDANI, YUKI, JP

    Free format text: FORMER OWNER: KIDANI, YOSHINORI, FUJISAWA, KANAGAWA, JP

    Effective date: 20120911

    Ref country code: DE

    Ref legal event code: R081

    Ref document number: 69713763

    Country of ref document: DE

    Owner name: KIDANI, YUKI, JP

    Free format text: FORMER OWNER: KIDANI, YOSHINORI, FUJISAWA, JP

    Effective date: 20120911

    Ref country code: DE

    Ref legal event code: R081

    Ref document number: 69713763

    Country of ref document: DE

    Owner name: YUKI KIDANI, JP

    Free format text: FORMER OWNER: YOSHINORI KIDANI, FUJISAWA, JP

    Effective date: 20120911

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: 732E

    Free format text: REGISTERED BETWEEN 20130103 AND 20130109

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: TP

    Owner name: YUKI KIDANI, GB

    Effective date: 20130208

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 19

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20160302

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20160309

    Year of fee payment: 20

    Ref country code: FR

    Payment date: 20160208

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R071

    Ref document number: 69713763

    Country of ref document: DE

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: PE20

    Expiry date: 20170309

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20170309